Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Phase 3 Completed 109 enrolled Tanabe Pharma Corporation Vertex Pharmaceuticals Incorporated · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.

Timeline

Start: 2008-11
Primary completion: 2010-10
Completion: 2010-10

Publications

Results Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012 Feb;19(2):e134-42. doi: 10.1111/j.1365-2893.2011.01528.x. Epub 2011 Nov 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telaprevir	Small molecule	750 mg	—
Background	Peginterferon alfa-2b	Protein / enzyme biologic	1.5 ug/kg	—
Background	Ribavirin	Small molecule	600 mg	—
Background	Ribavirin	Small molecule	1000 mg	—

Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Summary

Timeline

Publications

Drugs

Indications